Objective:The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists(AACE)Board of Directors and American College of Endocrinology(ACE)Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines(CPG).

Methods:Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors,according to established AACE/ACE guidelines for guidelines protocols.

Results:The Executive Summary of this 2020 updated guideline contains 52 recommendations:21 Grade A(40%),24 Grade B(46%),7 Grade C(14%),and no Grade D(0%).These detailed,evidence-based recommendations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world care of patients.The evidence base presented in the subsequent Appendix provides relevant supporting information for the Executive Summary recommendations.This update contains 368 citations:123(33.5%)EL 1(highest),132(36%)EL 2(intermediate),20(5.5%)EL 3(weak),and 93(25%)EL 4(lowest).New or updated topics in this CPG include:clarification of the diagnosis of osteoporosis,stratification of the patient according to high-risk and very high-risk features,a new dual action therapy option,and transitions from therapeutic options.

Conclusion:This guideline is a practical tool for endocrinologists,physicians in general,regulatory bodies,health-related organizations,and interested laypersons regarding the diagnosis,evaluation,and treatment of postmenopausal osteoporosis.

目的：这些指南的制定由美国临床内分泌医师协会 (AACE) 董事会和美国内分泌学会 (ACE) 董事会主办，并遵循已发布的 AACE 方案，以标准化制定临床实践指南 (CPG)。

方法：根据已制定的 AACE/ACE 指南方案，建议基于对临床证据的认真审查，并明确纳入主观因素。

结果：本2020年更新指南的执行摘要包含52项建议：21项 A 级 (40%)，24项 B 级 (46%)，7例 C 级 (14%) 和无 D 级 (0%)。这些详细的、基于证据的建议允许基于细微差别的临床决策，解决了患者现实世界护理的多个方面。后续附录中提供的证据基础为执行摘要建议提供了相关支持信息。该更新包含368条引文：123条 (33.5%)EL 1（最高）、132条 (36%)EL 2（中等）、20条 (5.5%)EL 3（弱）和93条 (25%)EL 4（最低）。该 CPG 中的新主题或更新主题包括：明确骨质疏松症的诊断、根据高风险和极高风险特征对患者进行分层、新的双重作用治疗选择和从治疗选择的转变。

结论：本指南是内分泌科医生、普通医生、监管机构、健康相关组织和有兴趣的非专业人员关于绝经后骨质疏松症诊断、评估和治疗的实用工具。